- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7157
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HEk293 cells | Function assay | Inhibition of human recombinant ADAMTS4 expressed in HEk293 cells using FAM-AEwLQGRPISIAK-TAMRA as substrate measured for 15 mins by fluorometric analysis, IC50=0.48 μM | 23376997 | |||
| U251 cells | Function assay | 20 μM | Protection against anthrax PA63-lethal toxin complex-induced cytotoxicity in human U251 cells at 20 uM at 400 ng/ml by MTT test | 17537721 | ||
| HEk293 cells | Function assay | Inhibition of human recombinant ADAMTS5 expressed in HEK293 cells using Abz-TESEwSRGAIY-Dpa-KK as substrate measured for 2 hrs by fluorometric analysis, IC50=0.5 μM | 23376997 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 78 mg/mL
(200.79 mM)
Ethanol : 8 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 388.46 | Formula | C20H28N4O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 142880-36-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Galardin | Smiles | CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC | ||
| Targets/IC50/Ki |
MMP-8
(Cell-free assay) 0.1 nM(Ki)
MMP-9
(Cell-free assay) 0.2 nM(Ki)
MMP-26
(Cell-free assay) 0.36 nM(Ki)
MMP-1
(Cell-free assay) 0.4 nM(Ki)
MMP-2
(Cell-free assay) 0.5 nM(Ki)
MMP-12
(Cell-free assay) 3.6 nM(Ki)
MMP-7
(Cell-free assay) 3.7 nM(Ki)
|
|---|---|
| In vitro |
Ilomastat (GM6001) inhibits human skin fibroblast collagenase with Ki of 0.4 nM when assayed with a synthetic thio ester substrate at pH 6.5, with 50-fold selectivity over two bacterial enzymes, thermolysin and Pseudomonas aeruginosa elastase. This compound (0.1 nM - 10 nM) inhibits gelatinase A and gelatinase B produced by T-cells, thus inhibits T-cell homing. |
| Kinase Assay |
Collagenase assay
|
|
Ilomastat (GM6001) is assayed using the synthetic thiol ester substrate Ac-Pro-Leu-Gly-SCH(i-Bu)CO-Leu-Gly-OEt at pH 6.5. The collagenase concentration is 1-2 nM, and the substrate concentrations are from 0.1 to 0.7 nM. Km is found to vary between 1.5 and 4 mM.
|
|
| In vivo |
Topical application of Ilomastat (GM6001) (400 μg/ml) prevents corneal ulceration after severe alkali injury. In rabbit model after stenting, it significantly inhibits intimal hyperplasia and intimalcollagen content, and increases lumen area in stented arteries without effects on proliferation rates. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot |